Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMY-920 for Relapsed or Refractory Non-Hodgkin Lymphoma
NCT05312801Phase 1Recruiting
- Sponsor
- Luminary Therapeutics
- Start
- Nov 2023
- Primary completion
- May 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BAFF CAR-T in non-Hodgkin lymphoma (NHL), sponsored by Luminary Therapeutics. Primary endpoint: Recommended Phase 2 Dose at 24 months. Started Nov 2023; status: recruiting.
02
Drugs
BAFF CAR-T
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05312801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05312801.